H2P DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, designed to manage gastrointestinal disorders characterized by acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea and vomiting. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, leading to prolonged reduction of gastric acidity. The synergistic effect of these two active ingredients makes H2P DSR Capsule effective in the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and other acid-related gastrointestinal conditions where delayed gastric emptying is a contributing factor. It is typically prescribed to alleviate symptoms such as heartburn, regurgitation, and epigastric discomfort. Administration should follow medical guidance to optimize therapeutic outcomes and minimize potential adverse effects. Caution is advised in patients with known hypersensitivity to any component, underlying cardiac conditions, or concurrent use of medications that may interact with domperidone or rabeprazole.